CXC™, a Montréal-based technology company focused on providing “Real Solutions to Real Problems,” announces the allowance of its proprietary chitosan suspension technology patent in Canada and Australia, with additional jurisdictions expected to follow. The milestone marks a significant step in the company’s efforts to advance the practical use of chitosan across skincare and other consumer applications through its CXC-SKIN platform technology.
According to François Lamoureux, CEO of CXC, the announcement reflects years of work addressing a longstanding scientific limitation. “For decades, natural biopolymers like chitosan have shown remarkable potential across multiple industries, but their non-solubility in neutral water has limited their real-world use,” he says. “What we have developed is a way to overcome that barrier and unleash chitosan’s documented superpowers, such as exceptional anti-aging properties.”
Lamoureux explains that chitosan, derived from natural sources, has been widely studied for being one of nature’s plastics. “These materials have long been recognized for their potential to displace petrochemicals and replace microplastics, but they have seen limited adoption except when used at very low concentrations. CXC-SKIN technology has solved this problem, and a number of Patent Offices around the world have agreed,” he says.
CXC’s technology is maturing at a perfect time, as evidenced by the recent product launches by a couple of large brands that contain or even feature chitosan. Lamoureux says, “The fact that some very big companies are deciding to use chitosan as a way to increase performance by natural means instead of relying on synthetic chemistry is good news. The great news for CXC-SKIN is that these brands’ new formulations typically contain less than 0.3% of chitosan, as noted in a recent company presentation. We solve a real problem here for the consumer because one doesn’t really see the superpowers of chitosan under concentrations of around 1.5%. We can go to 10% and beyond of chitosan suspended in water.”
He adds that the amount of chitosan in the formulation is key. “Chitosan’s efficacy is well-documented. With the high concentrations that the CXC-SKIN tech allows for, what we are seeing is botox-like results on fine lines and wrinkles, but without the botox. These kinds of results are absolutely consistent with a scientific article in the journal Cosmetics and peer-reviewed papers regarding chitosan, which number over 90,000,” Lamoureux states.
Lamoureux frames the patent allowance announcement as part of a broader trajectory. “This patent allowance is an important step, but it is part of a larger effort to bring practical solutions to industries that have been working around these limitations for years,” he says. “Our goal has always been to translate scientific potential into something that can be used reliably and at scale. Our technology is ready to be deployed and enjoyed by consumers who are tired of not seeing results from skincare products in relation to the price they are paying. Performance matters. CXC-SKIN’s chitosan suspension technology delivers on performance.”
CXC operates as a technology platform that identifies and develops intellectual property solutions to address real-world challenges, working with research institutions and commercial partners to bring innovations to market. With patent allowance now secured in multiple jurisdictions, CXC’s chitosan suspension technology is positioned to move further into commercialization discussions, as the company continues to expand its intellectual property footprint globally.
About CXC
CEO François Lamoureux leads CXC™, a Montréal-based technology company advancing practical applications of natural biopolymers. With a focus on solving long-standing scientific limitations, he has guided the development of CXC-SKIN, a patented chitosan suspension technology designed to improve performance in skincare and consumer products. Lamoureux’s work centers on translating well-documented scientific potential into scalable, real-world solutions, positioning CXC at the intersection of innovation, sustainability, and commercial application. For more information, visit cxcip.ca.
Media Contact
Marisa Kristofiak
marisa@cxcip.ca
